GP5

Across TCGA pan-cancer cohorts, GP5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GP5 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GP5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GP5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where GP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.807	0.244	.002	34	view →
LSCC	DFS	Quartile	All	1.000	0.283	.006	6	view →
LUAD	DFS	Tertile	All	0.751	0.514	.038	2	view →
UCEC	DFS	Median	All	0.678	1.000	.010	2	view →
HNSC	DFS	Median	III,IV	1.000	0.757	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GP5–CCRCC (DFS)

Open the CCRCC breakdown →